ARANESP DIN 02391821
Status: Marketed
Holder: AMGEN CANADA INC
Health Canada record
| Active ingredient(s) | DARBEPOETIN ALFA 500 MCG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous; Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | B03XA02 DARBEPOETIN ALFA |
|---|
| Original market date | 04-Nov-2013 |
|---|
| Current status date | 04-Nov-2013 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Amgen Canada Inc — licence 100048, currently licensed, last inspection rating C (2023-03-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DARBEPOETIN ALFA
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02392356 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 200 MCG | Marketed |
| 02246353 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 15 MCG | Approved |
| 02392313 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 25 MCG | Marketed |
| 02392321 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 40 MCG | Marketed |
| 02392348 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 100 MCG | Marketed |
| 02392364 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 500 MCG | Marketed |
| 02246359 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 325 MCG | Approved |
| 02246356 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 60 MCG | Approved |
| 02391732 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 40 MCG | Approved |
| 02391740 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 100 MCG | Marketed |
| 02391759 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 100 MCG | Marketed |
| 02391767 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 200 MCG | Marketed |
| 02391775 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 200 MCG | Marketed |
| 02391783 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 200 MCG | Marketed |
| 02391791 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 500 MCG | Marketed |
| 02391805 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 500 MCG | Marketed |
| 02391813 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 500 MCG | Approved |
| 02391848 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 500 MCG | Approved |
| 02246354 | ARANESP | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 25 MCG | Cancelled Post Market |
| 02246355 | ARANESP -(HSA-FREE) | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 40 MCG | Cancelled Post Market |
| 02246360 | ARANESP -(HSA-FREE) | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 500 MCG | Cancelled Post Market |
| 02246357 | ARANESP -(HSA-FREE) | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 100 MCG | Cancelled Post Market |
| 02246358 | ARANESP -(HSA-FREE) | AMGEN CANADA INC | Solution | DARBEPOETIN ALFA 200 MCG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 13668 | 2012-09-24 | Supplement to a New Drug Submission (SNDS) | New DIN |
Request a quote for ARANESP
How to read a Canadian DIN record